Some have relabeled it as Pentadecapeptide Aringate or PDA (changing the acetate to an arginate) and therefore are prescribing it for subcutaneous administration this way, although the confusion about its status has triggered a vivid oral capsule market for BPC in what appears to become a grey space of legality. https://lukasyiscl.bloguetechno.com/the-smart-trick-of-winstrol-vic-australia-that-nobody-is-discussing-73574301